ProCE Banner Activity

Expert Q&A – Asthma Management: Applying Phenotyping and Endotyping to Improve Outcomes in Uncontrolled Asthma

Text Module

During PCE's recent Pulmonary Bootcamp, attendees had the chance to ask our expert faculty a variety of questions about severe and uncontrolled asthma. Here, Ann Hefel, MS, FNP-BC, RN, instructor in the Department of Pediatric Allergy and Immunology at the University of Colorado School of Medicine, and Mark Liu, MD, associate professor of Medicine in the Division of Pulmonology and Critical Care Medicine at Johns Hopkins University, provide their responses to the questions asked during the live presentation. We hope you will find their responses relevant to your practice.

In Partnership With the Association of Pulmonary Advanced Practice Providers

APAPP Logo

Released: December 10, 2021

Expiration: December 09, 2022

Share

Acknowledgement

This program is cosupported by educational grants from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson; Genentech, a member of the Roche Group; GlaxoSmithKline; Jazz Pharmaceuticals, Inc.; and Mylan Specialty L.P.

This activity is supported by educational grants from Genentech, a member of the Roche Group; and GlaxoSmithKline.

Disclosure

Ms Hefel has no relevant financial relationships to disclose.

Dr Liu: consulting fees: AstraZeneca; contracted research/consulting fees: GlaxoSmithKline, Gossamer Bio.

Additional Information

Program Medium

This program has been made available online.